Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-kappaB Signaling in HCT116 Human Colorectal Cancer Cells
Intestinal Research
;
: 233-241, 2015.
Article
in English
| WPRIM
| ID: wpr-96060
ABSTRACT
BACKGROUND/AIMS:
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. Balsalazide can reduce inflammatory responses via several mechanisms, including inhibition of nuclear factor-kappaB (NF-kappaB) activity. Parthenolide (PT) inhibits NF-kappaB and exerts promising anticancer effects by promoting apoptosis. The present investigated the antitumor effects of balsalazide, combined with PT, on NF-kappaB in a representative human colorectal carcinoma cell line, HCT116.METHODS:
We counted cells and conducted annexin-V assays and cell cycle analysis to measure apoptotic cell death. Western blotting was used investigate the levels of proteins involved in apoptosis.RESULTS:
PT and balsalazide produced synergistic anti-proliferative effects and induced apoptotic cell death. The combination of balsalazide and PT markedly suppressed nuclear translocation of the NF-kappaB p65 subunit and the phosphorylation of inhibitor of NF-kappaB. Moreover, PT and balsalazide dramatically enhanced NF-kappaB p65 phosphorylation. Apoptosis, through the mitochondrial pathway, was confirmed by detecting effects on Bcl-2 family members, cytochrome c release, and activation of caspase-3 and -8.CONCLUSIONS:
Combination treatment with PT and balsalazide may offer an effective strategy for the induction of apoptosis in HCT116 cells.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphorylation
/
Colorectal Neoplasms
/
Inflammatory Bowel Diseases
/
Cell Cycle
/
Cell Line
/
Blotting, Western
/
NF-kappa B
/
Cell Death
/
Apoptosis
/
HCT116 Cells
Limits:
Humans
Language:
English
Journal:
Intestinal Research
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS